In Japanese clinical practice about CINV (Chemotherapy-induced Nausea and Vomiting), we have used some guidelines for antiemetic therapy overseas as a reference for many years. So, we sometimes have been confusing in clinical practice, but at last, we have been able to use the global standard antiemetic therapy as a result of the availability of long-active 5HT3 receptor antagonist Palonosetron (Palo) or neurokinin-1 antagonist Aprepitant (Apr). In adition, Japanese antiemetic therapy guideline was released by JAPAN SOCIETY OF CLINICAL ONCOLOGY in 2010,so the circumstance of the standard antiemetic therapy is getting prepared rapidly. However, the position of Palo and Apr is still controversial, so several studies about it are on going in Japan. Then Fosaprepitant that has effects similar to Aprepitant was given approval last year. So, we have got an another option to give a standard antiemetic therapy. In this symposium, I will give an explanation about the standard antiemetic therapy by introducing the evidence about these new antiemetics.